Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-4464 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MK-4464 + pembrolizumab is an investigational combination therapy for advanced or metastatic solid tumors, currently in Phase 1 clinical trials. MK-4464 is an antibody-based trifunctional molecule (TriNKET, developed by Dragonfly Pharmaceuticals) designed for immunotherapy in cancer. It binds to CEACAM5 on cancer cells and to NKG2D and CD16A on NK cells, thereby recruiting immune cells into tumors and directly activating the killing of cancer cells; it also engages cytotoxic T cells. Pembrolizumab is a programmed death-1 (PD-1) immune checkpoint inhibitor that enhances the immune response against cancer by blocking a pathway tumors use to evade immune destruction. Their combination aims to synergistically improve anti-tumor immune responses by both directly activating immune effector cells (via MK-4464) and removing immune suppression (via pembrolizumab)[2][1][3][5].
- Brand names
- Keytruda (for pembrolizumab)
- Other names
- MK4464 + pembrolizumab
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)NKG2D (Natural killer group 2 member D receptor)PDCD1 (Programmed cell death protein 1 receptor)CD244 (Natural killer cell receptor 2B4)
Beyond the preview
Go deeper on MK-4464 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-4464 + pembrolizumab.